• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Immunol . Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Cour

tetano

Editor, Senior Moderator
Eur J Immunol


. 2025 Apr;55(4):e202451497.
doi: 10.1002/eji.202451497. Distinct HLA Haplotypes Are Associated With an Altered Strength of SARS-CoV-2-Specific T-Cell Responses and Unfavorable Disease Courses

C Dörnte[SUP] 1 2 [/SUP], A Datsi[SUP] 3 [/SUP], V Traska[SUP] 1 [/SUP], J Kostyra[SUP] 1 [/SUP], M Wagner[SUP] 1 [/SUP], O Brauns[SUP] 1 [/SUP], C Lamsfuß[SUP] 1 [/SUP], H Winkels[SUP] 2 4 [/SUP], V Balz[SUP] 3 [/SUP], J Enczmann[SUP] 3 [/SUP], O Adams[SUP] 5 [/SUP], L Mueller[SUP] 5 [/SUP], H Baurmann[SUP] 1 [/SUP], B Eiz-Vesper[SUP] 6 [/SUP], A Bonifacius[SUP] 6 [/SUP], R V Sorg[SUP] 3 [/SUP], C Dose[SUP] 1 [/SUP], J Schmitz[SUP] 1 [/SUP], A Richter[SUP] 1 [/SUP], J Fischer[SUP] 3 [/SUP], M Schuster[SUP] 1 [/SUP]



Affiliations
Free PMC article Abstract

Infection with SARS-CoV-2 results in mild to severe COVID-19 disease courses. Several studies showed the association of impaired T-cell responses and certain HLA haplotypes with disease severity. However, it remained unclear if T-cell activation was compromised due to a general reduction of presented epitopes or other intrinsic factors within APCs or T cells. Furthermore, a potential reduction of presented epitopes would suggest if an upcoming SARS-CoV-2 variant could escape T-cell immunity. Hence, knowledge about the T-cell epitope landscape of SARS-CoV-2 would allow to better understand mechanisms leading to severe disease and to estimate the potential stability of the T-cell response in light of virus evolution, which might provide insights for future vaccine designs. Hence, in the present study, the T-cell epitope landscape of SARS-CoV-2 was determined via in vitro T-cell stimulation plus in silico prediction. HLAs associated with mild and severe disease courses showed almost the same potential in epitope presentation, suggesting intrinsic factors of APCs or T cells as contributors to the more severe disease courses. As T-cell epitopes did also not originate from regions of SARS-CoV-2 having shown high mutation rates in the past, a relatively stable T-cell response can be expected regarding new SARS-CoV-2 strains in the future. Analysis of the T-cell epitope landscape of SARS-CoV-2 suggests T-cell intrinsic factors as likely modulators of disease severity and that the capacity of MHC-peptide presentation remains stable among circulating SARS-CoV-2 viral strains.

Keywords: APC; HLA haplotypes; NetMHCpan; SARS‐CoV‐2; T‐cell immunity.

 
Back
Top Bottom